NeuroXess key facts
as of Oct 2026- Manufacturer of a brain-computer interface technology intended to advance neurological research and medical applications.
- NeuroXess is valued at approximately $48.4M as of Oct 2026 (last reported valuation).
- It has raised $15.2M; the latest was Early Stage VC in Feb 2026.
- Notable investors include HSG (Hong Kong), Yonghua Capital, New Alliance Capital, Chengdu Bio-Town Investment, Sailing Capital — 9 tracked in total.
- Status: Privately Held (backing).
NeuroXess's last reported valuation, Dec 2021. Nothing priced has surfaced since.
- ·Watch NeuroXess: the Monday email on marks, rounds and moves
NeuroXess funding rounds
No funding rounds for NeuroXess are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
NeuroXess valuation
NeuroXess's last reported valuation was $48.4 million in Dec 2021. No priced round, secondary trade or fund mark has surfaced since.
NeuroXess investors
9 investors are on record for NeuroXess, including HSG (Hong Kong), Yonghua Capital, New Alliance Capital and Chengdu Bio-Town Investment.
About NeuroXess
Manufacturer of a brain-computer interface technology intended to advance neurological research and medical applications. The company offers flexible implantable electrodes, silk-protein biomaterials, advanced decoding algorithms, and wireless systems, enabling healthcare institutions and research organizations to achieve precise neural interaction and improved patient rehabilitation.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Employees
- 70
- Website
- neuroxess.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.